Evidence map›Paper›PMID 39660680›Full record

ArticleAlimentary pharmacology & therapeutics2025

Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis.

Austin Haynesworth, Kuan-Hung Yeh, Han Hee Lee, Melissa Kirkpatrick, Brigid S Boland, Gaurav Syal, Ronghui Xu, Siddharth Singh

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Austin HaynesworthDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Kuan-Hung YehDivision of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Han Hee LeeDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Melissa KirkpatrickDepartment of Pharmacy, University of California San Diego, La Jolla, California, USA.
Brigid S BolandDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Gaurav SyalDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Ronghui XuBiostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California, USA.
Siddharth SinghDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-2640-7269

Funding

Comparative effectiveness research in Hispanic patients with inflammatory bowel diseasesR01DK135937 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Siddharth Singh · 2024 to 2026
$1.9M
Predicting Short- and Long-term Risk of Serious Infections in Older Patients with Inflammatory Bowel DiseasesR03DK129631 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2021 to 2022
$203k
NIDDK NIH HHS R01 DK135937NIDDK NIH HHS R01DK13593701A1NIDDK NIH HHS R03 DK129631NIDDK NIH HHS R03DK129631
6 · The paper itself

Abstract

backgroundAlthough studies have compared on-treatment effectiveness of infliximab and vedolizumab in patients with ulcerative colitis (UC), there has been limited comparison of treatment sequencing and long-term patient-centred outcomes.

aimTo compare infliximab-first and vedolizumab-first strategy in biologic-naïve patients with UC.

methodsWe conducted a retrospective cohort study in biologic-naïve patients with UC who were treated first with either infliximab or vedolizumab between 2015 and 2021 and followed over 30 months following initiation. Primary outcomes were the number of hospitalisations, corticosteroid courses and serious infections with either strategy (regardless of switch to alternative therapies) within 30 months. We matched the groups 1:1 through cardinality matching, and fit logistic and zero-inflated negative binomial models to compare outcomes.

resultsWe included 181 patients (94 vedolizumab-first and 87 infliximab-first treatment strategy). Of these, 144 were matched 1:1. There was no significant difference in the incidence of IBD-related hospitalisations (incidence rate ratio [IRR], 1.98 [95% CI, 0.64-6.10]), corticosteroid courses (0.66 [0.38-1.15]) and serious infections (5.26 [0.62-45.45]), with comparable incidence of medication switches to alternative advanced therapies (1.08 [0.42-2.81]). At 30 months, there was no difference in proportion of patients in clinical remission (69.4% vs. 76.4%; p = 0.45) and endoscopic remission (55.6% vs. 65.3%; p = 0.36).

conclusionIn patients with UC, long-term effectiveness and safety outcomes are comparable with infliximab-first and vedolizumab-first treatment strategies at 30 months. This can help to guide selection of treatment strategies in patients with UC.

Indexed as

Antibodies, Monoclonal, HumanizedColitis, UlcerativeGastrointestinal AgentsInfliximabAdultFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedGastrointestinal AgentsInfliximabvedolizumabinfliximabulcerative colitisvedolizumab

Identifiers

PMID39660680
PMCPMC12186699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.